CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive: High levels of CIP2A at diagnosis are significantly associated with risk of progressing to blast crisis; therefore, the CIP2A protein level has been proposed as a prospective biomarker of disease progression in imatinib-treated CML patients (108).